Global Biologics Market: Snapshot
The biologics market is expected to grow at an impressive pace during the forecast period. The gains will be driven by substantial investments in research and developmental activities in the biotechnology and pharmaceutical sector and the soaring demand for novel therapies for various rare diseases. Recent intensive researches in novel therapies and combination therapies have established the efficacy of biologics for treating a wide range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration, and hematological malignancies. The introduction of recombinant DNA technology has expanded the potential of the biologics market. The emergence of promising drug candidates has made several global and regional pharmaceutical players venture into the biologics market. The increasing rate of approval of biologics by various regulatory agencies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) has positively impacted the market.
The global biologics market is forecast to expand at a CAGR of 10.9% over the period 2016 – 2024. Maintaining a steady pace of growth, the market is anticipated to attain a valuation of US$479, 752 mn by the end of the forecast period.
Several players are making large investments in expanding their biologics facilities across major geographic regions to gain a stronghold in this market. Leading players are launching novel therapies approved by the FDA to gain a competitive edge over others. The top biotechnology and pharmaceutical companies are forging partnerships to consolidate their shares across various regions.
Global Biologics Market: Scope and Methodology
This report provides forecast and analysis of the global biologics market on the global and regional levels. It provides historical data of 2015 along with forecast from 2016 to 2024 in terms of revenue (US$ Mn). The report also includes macroeconomic indicators along with an outlook for biologics revenue annually. It includes drivers and restraints of the global biologics market and their impact on each region during the forecast period. The report also comprises the study of applications and opportunities for biologics manufacturers. It also includes a detailed analysis by product type and supply chain analysis with a list of suppliers and industry stakeholders at each node in the supply chain.
In order to provide users of this report with a comprehensive view of the market, we have included detailed competitiveness analysis, key blockbuster products, clinical pipeline analysis and company players with unique propositions. The dashboard provides a comprehensive comparison of biologics manufacturers on parameters such as revenue sales, ranking of global players, strategic consolidations, i.e. mergers & acquisitions, licensing activities, as well as R&D activities. The study encompasses market attractiveness analysis, product type, application type, and region.
This exhaustive report includes 18 data tables and 101 figures to give readers a 360° view of the Biologics Market. Browse through this 179-page report to know what factors will shape the market during the period 2016-2024
Global Biologics Market: Segmentation
The report includes the revenue generated from sales of biologics in all regions and important countries in these regions. By product, the global biologics market has been segmented into monoclonal antibodies, vaccines, recombinant hormones/vaccines, cell therapy, gene therapy and other products. By application type, the market is segmented into oncology, infectious diseases, immunology, auto-immune diseases, and other diseases. Furthermore, the global market is sub-segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Market numbers have been estimated based on the annual global and regional sales of key companies; annual production and the revenue of local players is derived from regional pricing trends. Market size and forecast for each segment have been provided in the context of global and regional markets. The global biologics market has been analyzed based on expected demand. Prices considered for the calculation of revenue are regional average prices obtained through primary quotes from numerous regional biologics manufacturers, suppliers, and distributors. All key end users have been considered, and potential applications have been estimated on the basis of secondary sources and feedback from primary respondents. Regional demand patterns have been taken into consideration while assessing the market for various products manufactured in different regions. Top-down approach has been used to estimate the biologics market by regions. Market numbers for global product type and application segments have been derived using the bottom-up approach, which is cumulative of each region’s demand. The company-level market share has been calculated on the basis of revenues reported by key manufacturers. The market has been forecast based on constant currency rates.
Several primary and secondary sources were consulted during the course of the study. Secondary sources include Factiva, World Bank, FDA, NCBI, Springer Journals, Google Books, Society Publications, Biotechnology Innovation Organization, Arthritis Foundation, British Society for Rheumatology and Hoover’s, as well as company annual reports and publications.
Global Biologics Market: Competitive Landscape
The report provides detailed competitive and company profiles of key participants operating in the global market. Key players in the global biologics market include AbbVie Inc., Amgen Inc, AstraZeneca, Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi.
Request a sample of this report to know what opportunities will emerge in the rapidly evolving Biologics Market during 2016- 2024
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453